JSPR — Jasper Therapeutics Income Statement
0.000.00%
- $305.33m
- $186.86m
- 36
- 19
- 88
- 45
Annual income statement for Jasper Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.21 | 20.7 | 36.8 | 51.2 | 68.9 |
Operating Profit | -5.21 | -20.7 | -36.8 | -51.2 | -68.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.99 | -31.7 | -30.6 | -37.7 | -64.5 |
Net Income After Taxes | -4.99 | -31.7 | -30.6 | -37.7 | -64.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.99 | -31.7 | -30.6 | -37.7 | -64.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.99 | -31.7 | -30.6 | -37.7 | -64.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.19 | -8.37 | -8.09 | -10.3 | -6.18 |